Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07094113 · ClinicalTrials.gov registry record · Phase 1
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
A Phase 1 study of KRAS Altered Advanced or Metastatic Solid Tumors, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 434
- Enrollment target
- 20
- Study locations
NCT07094113: Recruiting Phase 1 study of KRAS Altered Advanced or Metastatic Solid Tumors, sponsored by Amgen.
NCT07094113 is a Phase 1 study of KRAS Altered Advanced or Metastatic Solid Tumors that is actively recruiting participants, run by Amgen. The registered enrollment target is 434 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (623% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07094113, a Phase 1 study of KRAS Altered Advanced or Metastatic Solid Tumors, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 434 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AMG 410 when administered alone or in combination with other agents in participants with advanced or metastatic solid tumors harboring KRAS alterations. This is a dose-escalation study in which participants will be assigned to multiple dose levels (DLs) of AMG 410, either as monotherapy or in combination with other agents, followed by expansion cohorts. The goal is to determine the Maximum Tolerated Dose (MTD)-the highest dose with acceptable safety and manageable side effects-or the Recommended Phase 2 Dose (RP2D) of AMG 410 in adult participants with KRAS-altered advanced or metastatic solid tumors.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Panitumumab
- DRUG AMG 410
Study Locations (20)
Other
- Universitair Ziekenhuis Gent - Ghent
- Rigshospitalet - Copenhagen
- Centre Leon Berard - Lyon
- Gustave Roussy - Villejuif
- Universitaetsklinikum Essen - Essen
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda - Milan
California
- City of Hope National Medical Center - Duarte
Georgia
- Emory University - Atlanta
Massachusetts
- Massachusetts General Hospital - Boston
Missouri
- Siteman Cancer Center - Washington University - St Louis
North Carolina
- Duke Cancer Center - Durham
Pennsylvania
- Thomas Jefferson University - Philadelphia
Tennessee
- Sarah Cannon Research Institute Oncology Partners - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 434 participants |
| Start Date | 2025-07-31 |
| Est. Completion | 2031-04-20 |
| Phase | Phase 1 |
What NCT07094113 shows while recruiting
NCT07094113 is an interventional study that assigns participants to a tested intervention. The registered 434 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (623% higher).
The record links to 1 condition, with KRAS Altered Advanced or Metastatic Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT07094113 names 20 study sites across 15 states, led by Other, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT07094113 about?
NCT07094113 is a clinical study titled "AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors". The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AMG 410 when administered alone or in combination with other agents in participants with advanced or metastatic solid tumors harboring KRAS alte...
What is the current status of trial NCT07094113?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 434 participants. The study started on 2025-07-31. Estimated completion is 2031-04-20.
What conditions does trial NCT07094113 study?
This clinical trial studies the following conditions: KRAS Altered Advanced or Metastatic Solid Tumors.
What interventions are being tested in trial NCT07094113?
The interventions under investigation include: Pembrolizumab (DRUG), Panitumumab (DRUG), AMG 410 (DRUG).
Who is sponsoring clinical trial NCT07094113?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07094113 being conducted?
This trial has 20 study locations across California, Georgia, Massachusetts, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07094113's enrollment target sits among peer trials
434 63rd of 2000 higher than 1,938 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04743245 · 434 participants · NA
Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.
- NCT06471920 · 434 participants · NA
Improving Health for Patients With Chronic LBP in Rural Communities Through Telerehabilitation
- NCT05563220 · 435 participants · Phase 1
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
- NCT07088926 · 435 participants · Phase 2
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI